BenevolentAI
multiple machine learning models expand the target universe expands pool of possible targets by approaching target cation from different angles some models can rank the entire human genome provide promising targets that answer biological questions reveals novel drug targets that have never been considered for a disease before modality agnostic the benevolent platform can be applied to antibodies and other biologic agents in addition to small molecules | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
10 of 29
Related slides by other companies
Oak Street Health
IPO
July 2020
investment highlights large senior focused market opportunity with significant white space purpose built value based care platform supported by end to end technology nationally scalable model with systematic approach to new market development multiple drivers of robust long term growth highly predictable unit economics drive compelling financial model mission driven leadership team with unique oaky culture | Oak Street Health
Embark
SPAC
June 2021
embark best self driving is focused on building the | Embark
Exscientia
Results
August 2022
our differentiated approach leads to technology platform a | Exscientia
Adagio Therapeutics
Investor Conference
March 2023
building on our vision to create the perpetual machine | Adagio Therapeutics
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io